Multiple markers of hypercoagulation in patients with history of venous thromboembolic disease

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 1, 2013, Pages 59-63

  Bern, Murray ^a,b   McCarthy, Nancy ^b  

^a New England Baptist Hospital   (United Kingdom)

^b NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

deep vein thrombosis; hypercoagulation; pulmonary embolus; thromboembolism; thrombosis

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; PROTEIN C;

ARTICLE; HEMATOLOGY; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODIES, ANTICARDIOLIPIN; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; DIAGNOSTIC TESTS, ROUTINE; FACTOR V; HOMOCYSTEINE; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREOPERATIVE CARE; PROTEIN C; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84871818107     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835a72aa     Document Type: Article

References (59)

1. Wautrecht JC. Venous thromboembolic disease: which coagulation screening, for whom, when? Rev Med Brux 2005; 26:S315-S319.
2. Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009; 301:2472-2485.
3. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166:729-736.
4. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haemtol 2005; 131:80-90. (Pubitemid 43899712)
5. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, et al. Screening for thrombophilia in high-risk situations: systematic review and cost effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10:1-110.
6. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44:62-69. (Pubitemid 46553809)
7. Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovick T, Pabinger I. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 2007; 92:374-380. (Pubitemid 350143547)
8. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998; 80:382-387. (Pubitemid 28438729)
9. Slamon N, Krueger LJ, Edelson M, Glutting JJ, Rittenhouse D. A retrospective study of the risk factors associated with hypercoagulability in the pediatric patients at a tertiary care children's hospital. Pediatr Crit Care Med 2008; 9:511-516.
10. Fritch P, Kleber M, Rosenkranz A, Fritch M, Muntean W, Magge H, Reinehr T. Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation and fibrinogen levels. Atherosclerosis 2010; 212:650-655.
11. Cuderman TV, Bozic M, Peternel P, Stegnar M. Hemostasis activation in thrombophilic subjects with and without a history of venous thrombosis. Clin Appl Thromb Hemost 2008; 14:55-62.
12. Decousus H, Qué ré I, Presles E, Becker F, Barrellier MT, Chanut M, et al., for the POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Superficial venous thrombosis and venous thromboembolism. A large, prospective epidemiologic study. Ann Intern Med 2010; 152:218-224.
13. Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007; 5:937-941. (Pubitemid 46691722)
14. van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14:413-418. (Pubitemid 34439042)
15. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63:273-278. (Pubitemid 23082067)
16. Gillet JL, Perrin M, Cayman R. Superficial venous thrombosis of the lower limbs: prospective analysis in 100 patients. J Mal Vasc 2001; 26:16-22. (Pubitemid 32209771)
17. Kreidy R, Waked M, Stephan E, Irani J, Chemali R, Jureidini I, Irani-Hakime N. Acquired and genetic risk factors for deep vein thrombosis of lower extremities among Lebanese. J Med Liban 2012; 60:24-29.
18. Price DT, Ridker PM. Factor V Leiden mutation and the risks of thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127:895-903. (Pubitemid 27490627)
19. Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110:566-570. (Pubitemid 39031174)
20. Nowak-Göttl U, Junker R, Kreuz W, von Eckarstein A, Kosch A, Nohe N, et al.; Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001:97:858-862. (Pubitemid 32154265)
21. Bogdanova N, Markoff A. Hereditary thrombophilic risk factors for recurrent pregnancy loss. J Community Genet 2010; 1:47-53.
22. Zö ller B, Garcia de Frutos P, Hillarp A, Dahlbäck B. Thrombophilia as a multigenic disease. Haematologica 1999; 84:59-70. (Pubitemid 29479383)
23. Kreidy R, Irani-Hakime N. Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients? Vasc Health Risk Manag 2009; 5:627-633.
24. Jennings I, Kitchen S, Woods TA, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 2005; 31:66-72. (Pubitemid 40262139)
25. Zöller B, Garcia de Frutos P, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemostas 1998; 79:802-807. (Pubitemid 28163858)
26. Castañon MM, Lauricella AM, Kordich L, Quintana I. Plasma homocysteine cutoff values for venous thrombosis. Clin Chem Lab Med 2007; 45:232-236. (Pubitemid 46294689)
27. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: implications and therapeutic implications. Haematologica 2002; 87:1095-1108. (Pubitemid 35192223)
28. Somma J, Sussman II, Rand JH. An evaluation of thrombophilia screening in an urban Tertiary care medical center: a 'real world' experience. Am J Clin Pathol 2006; 126:120-127. (Pubitemid 44025080)
29. De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A, Leone G. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C, and protein S. Haematologica 2006; 91:695-698. (Pubitemid 43799473)
30. Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 2008; 37:19-30. (Pubitemid 351341137)
31. Lijfering WM, Coppens M, van de Poel MH, Middeldorp S, Hamulyák K, Bank I, et al. The risk of venous and arterial thrombosis in hyperhomocysteinemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98:457-463. (Pubitemid 47250250)
32. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762. (Pubitemid 26089357)
33. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80:874-877. (Pubitemid 28556684)
34. Ringwald J, Berger A, Adler W, Kraus C, Pitto RP. Genetic polymorphisms in venous Thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study. Clin Orthop Relat Res 2009; 467:1507-1515.
35. Okumus G, Kiyan E, Arseven O, Tabak L, Diz-Kucukkaya R, Unlucerci Y, et al. Hereditary thrombophilic risk factors and venous thromboembolism in Istanbul, Turkey: The role of different clinical manifestations of venous thromboembolism. Clin Appl Thromb Hemost 2008; 14:168-173. (Pubitemid 351364016)
36. Mateo J, Oliver A, Borrell M, Sala H, Fontcuberta J. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). Blood Coagul Fibrinolysis 1998; 9:71-78. (Pubitemid 28144419)
37. Dumenco LL, Blair AJ, Sweeney JD. The results of diagnostic studies for thrombophilia in a large group of patients with a personal or family history of thrombosis. Am J Clin Path 1998; 110:673-682. (Pubitemid 28491974)
38. Segal JB, Brotman DJ, Emadi A, Necochea AJ, Samal L, Wilson LM, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism. Evid Rep Technol Asses 2009; 180:1-162.
39. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92:1107-1114. (Pubitemid 350144218)
40. Božič M, Stegnar M, Fermo I, Ritonja A, Peternel P, Stare J, D'Angelo A. Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism. Thromb Res 2000; 100:271-278.
41. Ueland PM, Refsum H, Stabler S, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39:1764-1779. (Pubitemid 23277003)
42. Oger E, Lacut K, Le Gal G, Couturaud F, Guénet D, Abalain JH, et al., Edith Collaborative Study Group. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost 2006; 4:793-799.
43. Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80:566-569. (Pubitemid 28479339)
44. Eichinger S. Homocysteine, vitamin B6, and risk of recurrent venous thromboembolism. Pathophysiol Haemost Thromb 2003/2004; 33:342-344. (Pubitemid 40278705)
45. Ocal IT, Sadeghi A, Press RD. Risk of venous thrombosis in carriers of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductace. Mol Diag 1997; 2:61-68. (Pubitemid 127734938)
46. Doig RG, O'Malley CJ, Dauer R, McGrath KM. An evaluation of 200 consecutive patients with spontaneous or recurrent thrombosis for primary hypercoagulation states. Am J Clin Pathol 1994; 102:797-801.
47. Bern MM, McCarthy N. Failure to lyse venous thrombi because of elevated plasminogen activator inhibitor 1. (The PAI-1/4G Syndrome). Clin Appl Thromb/Hemo 2010; 16:574-578.
48. Rahemtullah A, Van Cott EM. Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med 2007; 131:890-901. (Pubitemid 46906380)
49. Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex disorder. Semin Hematol 1997; 34:256-264.
50. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2, 132 consecutive unselected patients with venous thromboembolism-Results of the Spanish Multicentric Study of Thrombophilia (EMET*-Study). Thromb Haemost 1997; 77:444-451. (Pubitemid 27121006)
51. Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg 2010; 199:S3-10.
52. Behair H, Berli M, Gezer S, Jacobs JJ, Della Valle CJ. Hematologic genetic testing in high risk patients before knee arthroplasty: a pilot study. Clin Orthop Relat Res 2011; 469:131-137.
53. Linnemann B, Schindewolf M, Zgouras D, Erbe M, Jarosch-Preusche M, Lindhoff-Last E. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis? Thromb Res 2008; 121:743-750. (Pubitemid 351492581)
54. Mira Y, Vayá A, Mafrtinez M, Villa P, Santaolaria ML, Ferrando F, Aznar J. Hemorheological alterations and hypercoagulable state in deep vein thrombosis. Clin Hemorheol Microcirc 1998; 19:265-270. (Pubitemid 29039424)
55. Shumakov VI, Cheurov AK. Characteristics of hemocoagulation in different periods of the development of a venous intravascular thrombus. Probl Gematol Pereliv Krovi 1975; 20:24-30.
56. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448.
57. Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B 2005; 6:1045-1056. (Pubitemid 43083934)
58. Lison S, Weiss G, Spannagl M, Heindl B. Postoperative changes in procoagulant factors after major surgery. Blood Coagul Fibrinolysis 2011; 22:190-196.
59. Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol 2006; 163:334-341. (Pubitemid 43238427)